KRAS and cancer: Several other Phase 1, 2, and 3 trials are further evaluating the efficacy and safety of single agent Adagrasib and in combination with Docetaxel, Palbociclib, Cetuximab, BI 1701963, and TNO155 in KRAS G12C mutated cancers [56,57,58,59].